Investment Rating - The report does not explicitly provide an investment rating for the industry or specific companies within it. Core Insights - The 2025 Q4 Lyst ranking indicates a consumer shift towards brands that emphasize stability, classic styles, and practicality, moving away from short-term trends [2][12] - The top three brands, Saint Laurent, Miu Miu, and COS, maintained their positions, reflecting consumer preference for brands with clear style boundaries and consistent aesthetic expression [2][12] - Mid-tier brands like Ralph Lauren and Burberry saw significant improvements, attributed to a return to classic styles and strong holiday gifting demand [2][12][13] - The overall trend suggests a transition in the fashion industry from "visual shock value" to "Borecore," where classic, durable, and versatile items are becoming mainstream choices [2][12] Summary by Sections Brand Rankings - The top three brands in the Lyst ranking for Q4 2025 were unchanged: Saint Laurent, Miu Miu, and COS [1][11] - Ralph Lauren rose five places to rank fourth, while Burberry and Gucci each climbed five places to eighth and ninth, respectively [1][11] - Notable declines were seen in brands like Bottega Veneta and Loewe, each dropping five places [1][11] Consumer Preferences - Consumers are increasingly favoring brands that offer clear style definitions and consistent aesthetics, moving away from fleeting trends [2][12] - The demand for classic and practical items is on the rise, with brands like Ralph Lauren and Burberry benefiting from this shift [2][12][13] Item Popularity - The report highlights that practical outerwear and knitwear are leading in item popularity, with specific products like Polo Ralph Lauren's half-zip cable-knit sweater and Burberry's wool scarf gaining significant attention [8][14] - Accessories such as Burberry cashmere scarves and Arc'teryx knit beanies also maintained high interest, with Arc'teryx searches surging by 1,058% in Q4 [8][14]

[Table_Title] 研究报告 Research Report 10 Feb 2026 中国半导体 China (Overseas) Semiconductor FY4Q25 全球科技业绩快报：安森美 FY4Q25 Global Semiconductor Earnings Snapshot: ON Semiconductor 姚书桥 Barney Yao barney.sq.yao@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件 安森美 4Q25 业绩整体表现稳健：4Q25 收入为$15.3 亿，略高于$15.35 亿的市场一致预期；非公认会计准则每股收益 （non-GAAP EPS）为$0.64，超出$0.62 的市场共识；盈利能力稳步提升，GAAP 毛利率达 36%，non-GAAP Gross Margin 进一步提升至 38.2%，已初步显现晶圆优化措施的成效，整体业绩表现超出公司此前业绩指引中值。 点评 AI Datacen ...

[Table_Title] 研究报告 Research Report 9 Feb 2026 信达生物 Innovent Biologics (1801 HK) 信达生物与礼来达成第七次全球战略合作，合作规模超预期 Innovent and Eli Lilly Forge Their Seventh Global Strategic Collaboration; Deal Size Beats 孟科含 Kehan Meng 聂照亿 Zhaoyi Nie kh.meng@htisec.com john.zy.nie@htisec.com 从引进来，到走出去：这是信达与礼来的第七次合作。这种"中国 PoC+全球开发"的分工，充分发挥了信达在中国 高效的临床能力，降低了信达的海外开发风险，同时凭借礼来的全球网络提升效率。本次合作为信达主导早期研 发并保留大中华区权益，标志着其研发能力获国际认可，是中国创新药企全球化能力提升的关键一步。 战略意义超越单次交易：首付款与里程碑款将强化信达的财务安全垫，销售分成使其长期受益于全球市场增长。 合作聚焦的肿瘤与免疫领域，可与信达现有核心管线，如 IBI363（PD1/IL2）、 ...

研究报告 Research Report 9 Feb 2026 香港医疗 Hong Kong Health Care 医药行业周报（2026.02.02-2026.02.06）：市场情绪回暖；看好基本面表现强劲的创新药产业链龙头 Healthcare Weekly (2026.02.02-2026.02.06): Market Sentiment Warms; Bullish on Leaders in Innovative Drug Chain with Strong Fundamentals [Table_yemei1] 观点聚焦 Investment Focus | [Table_Info] | | | | | --- | --- | --- | --- | | 股票名称 | 评级 | 股票名称 | 评级 | | 百济神州 | Outperform 华润医药 | | Outperform | | 京东健康 | Outperform 国药控股 | | Neutral | | 药明生物 | Outperform 映恩生物 | | Outperform | | 信达生物 | Outperform 金斯瑞生物科 ...

Investment Rating - The report maintains a positive outlook on e.l.f. Beauty, indicating an upgrade in full-year net sales growth guidance from 18%-20% to 22%-23% due to the strong contribution from the Rhode acquisition [2][9]. Core Insights - e.l.f. Beauty reported a 38% year-over-year increase in net sales for FY26Q3, reaching $489.5 million, with the Rhode acquisition contributing approximately $128 million [2][9]. - The core organic net sales growth was only about 2%, which is below expectations, primarily due to short-term softness in key international markets like the UK and Germany [2][9]. - The company has adjusted its global consumption growth expectation down to 6% from 8%, reflecting a marginal weakening in the broader consumer environment [2][9]. - Adjusted EBITDA rose 79% to $123 million, representing 25% of net sales, showcasing the company's ability to maintain strong performance over 28 consecutive quarters of year-over-year net sales growth [2][9]. Financial Performance - Gross margin for FY26Q3 decreased by 30 basis points to 71%, mainly due to higher tariff costs, but was partially offset by pricing and product mix optimization [3][10]. - Selling, general, and administrative (SG&A) expenses as a percentage of net sales decreased from 54% to 51%, attributed to improved marketing efficiency and timing shifts of some expenses [3][10]. - The company reported a net income of $39.4 million and an adjusted net income of $74.5 million, with diluted earnings per share at $0.65 and adjusted diluted earnings per share at $1.24 [3][10]. Brand and Market Dynamics - e.l.f. Cosmetics brand achieved an 8% year-over-year increase in U.S. consumption, significantly outpacing the overall color cosmetics category growth of 4% [4][11]. - The company has established a dominant 22% market share in the face makeup segment, with substantial growth potential in lip and eye categories [4][11]. - The Rhode brand has set records for the largest brand launch in Sephora's history in North America and the UK, indicating strong market acceptance [4][11]. Innovation and Marketing Strategy - e.l.f. continues to leverage community insights for product innovation, with new products priced competitively against high-end counterparts, generating positive feedback [5][12]. - Marketing initiatives, including collaborations and campaigns, have resulted in over 4 billion impressions, showcasing the effectiveness of their marketing strategy [5][12]. International Market Potential - International sales currently account for about 20% of total sales, indicating significant growth potential compared to the industry average of over 70% [6][13]. - The company has established a comprehensive distribution network in Germany and is expanding its presence in Australia/New Zealand with the Rhode brand [6][13]. - Despite short-term pressures in the UK market, the company is implementing strategies to strengthen its value proposition and enhance brand awareness [6][13].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others [1]. Core Insights - The report highlights that overseas consumer earnings releases have led to stock price volatility, with A/H shares anticipating a recovery in discretionary consumption in 2026 [1]. - The performance of various sectors is analyzed, with gaming, U.S. hotels, snacks, and retail showing positive trends, while luxury goods and overseas cosmetics are experiencing declines [4][12]. - The report notes that the valuation of discretionary consumption sectors remains below the average of the past five years, indicating potential investment opportunities [10]. Sector Performance Summary - **Gaming Sector**: Increased by 5.5%, driven by strong growth in gross gaming revenue and positive earnings from major companies like MGM China [6][14]. - **U.S. Hotels**: Also up by 5.5%, with positive earnings forecasts from Marriott and Hilton [14]. - **Snacks Sector**: Rose by 3.6%, with companies like Youyou Foods and Qiaqia Foods showing strong sales growth [14]. - **Retail Sector**: Increased by 3.5%, led by Walmart and Target, which reported better-than-expected same-store sales [14]. - **Domestic Sportswear**: Grew by 2.6%, with Li Ning benefiting from its partnership with the Chinese Olympic Committee [14]. - **Credit Card Sector**: Up by 2.3%, supported by strong earnings from Visa and Mastercard [14]. - **Domestic Cosmetics**: Increased by 2.1%, benefiting from the overall strength in the beauty and skincare sector [14]. - **Luxury Goods**: Slightly up by 0.9%, influenced by a rebound in the U.S. market [14]. - **Overseas Sportswear**: Increased by 0.7%, with Nike announcing the opening of its first ACG store in Beijing [15]. - **Pet Sector**: Decreased by 0.7%, with companies like Guobao Pet and Zhongchong Co. facing declines [15]. - **Gold and Jewelry**: Down by 1.2%, affected by fluctuations in gold prices [15]. - **Overseas Cosmetics**: Fell by 5.7%, with Estée Lauder experiencing a significant drop [15].

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

Revenue Performance - MGM China reported total revenue of HKD 9.62 billion in 25Q4, a year-on-year increase of 21.4%[1] - For the full year 2025, total revenue reached HKD 34.79 billion, up 10.8% year-on-year[1] EBITDA Growth - Adjusted EBITDA for 25Q4 was HKD 2.75 billion, reflecting a year-on-year increase of 29.5%[1] - The adjusted EBITDA margin improved to 28.6%, up 1.78 percentage points year-on-year[1] Gaming and Non-Gaming Contributions - Gaming revenue contributed HKD 8.46 billion, a 23.0% increase year-on-year, while non-gaming revenue was HKD 1.15 billion, up 10.9%[2] - By property, MGM Macau and MGM Cotai generated revenues of HKD 3.48 billion (+4.1% YoY) and HKD 6.14 billion (+34.1% YoY) respectively[2] Betting Trends - Total betting amount reached HKD 80.16 billion, a 9.9% increase year-on-year[3] - VIP betting increased by 5.7% to HKD 30.64 billion, while mass market betting rose by 13.2% to HKD 31.52 billion[3] Market Share and Customer Insights - MGM China's market share reached 16.5% in 25Q4, up 1.0 percentage points from 15.5% in 25Q3[5] - Management anticipates strong demand during the upcoming Chinese New Year, with robust hotel booking trends observed[6]

Investment Rating - The report assigns a positive investment rating to Coherent, indicating an expectation of outperforming the market in the next 12-18 months [19]. Core Insights - Coherent delivered an outstanding performance in FY2Q26, achieving revenue of $1.69 billion, surpassing the consensus estimate of $1.64 billion, and setting a new record high. Non-GAAP EPS reached $1.29, exceeding the market expectation of $1.20. The non-GAAP gross margin climbed to 39%, reflecting strong profitability driven by lower raw material costs and improved operational efficiency [1][8]. Summary by Relevant Sections Financial Performance - In FY2Q26, Coherent's revenue was $1.69 billion, exceeding expectations and marking a historical high. Non-GAAP EPS was $1.29, above the anticipated $1.20. The gross margin increased to 39%, benefiting from reduced raw material costs and enhanced production efficiency [1][8]. Business Segments - The data center and communications business segment accounted for over 70% of total revenue, with a revenue increase of 14% quarter-over-quarter and 36% year-over-year, driven by strong demand for 800G and 1.6T optical modules [2][9]. Order Demand - The order-to-shipment ratio for the data center business exceeded 4:1, with demand visibility at an all-time high. Orders are scheduled through the end of 2026, with significant long-term demand forecasts from major customers extending into 2028 [3][10]. Capacity Expansion - Coherent aims to double its internal InP production capacity by Q4 2026, currently achieving 80% of this target ahead of schedule. The 6-inch InP production line shows significant advantages, including a fourfold increase in chip output compared to 3-inch wafers [4][11]. Future Outlook - For FY3Q26, Coherent expects revenue between $1.7 billion and $1.84 billion, in line with market consensus. The non-GAAP gross margin is projected to be between 38.5% and 40.5%, maintaining profitability advantages. Non-GAAP EPS is anticipated to reach $1.28 to $1.48, exceeding the consensus of $1.40 [5][12].

研究报告 Research Report 6 Feb 2026 中国 & 中国 & 香港服装、鞋类及配饰设计 China (A-share) & China (Overseas) & Hong Kong Apparel, Footwear & Acc Design 中国服饰鞋类企业如何在东南亚实现海外品牌和渠道落地 Southeast Asian Apparel Industry Research: How do Chinese Apparel and Footwear Brands Realize Brand and Channel Landing in Oversea Market [Table_yemei1] 观点聚焦 Investment Focus | 股票名称 | 评级 | 股票名称 | 评级 | | --- | --- | --- | --- | | 安踏体育 | Outperform 开润股份 | | Outperform | | 安踏体育 | Outperform 健盛集团 | | Outperform | | 申洲国际 | Outperform 歌力思 | | Outperform | | ...